Healthcare & Biotech
Today in Healthcare & Biotech· Nov 22
GLP-1 drugs are reshaping consumer eating patterns and pressuring casual dining chains. Pizza restaurants report weakened demand as appetite-suppressing medications alter customer behavior, compounding existing headwinds from delivery competition and broader discretionary spending weakness. The sector faces margin compression as lower traffic and reduced order sizes hit valuations across casual dining.
Drug development, pharma deals, obesity drugs, health tech and healthcare services.
66 events across this topic and its sub-topics
Show all 11 sub-topics
What the Market Says
- Will the FDA approve retatrutide? ↗
- 90%Before Jan 1, 2029
- 89%Before Jul 1, 2028
- 71%Before Jan 1, 2028
Earliest close Jan 1, 2027
Prices from Kalshi prediction markets: the market-implied chance of each outcome, set by traders, not a forecast or advice from Penblock. Penblock is not affiliated with Kalshi.
- Single sourceabout 8 hours ago
Pizza chains battle weak demand, delivery rivals, and GLP-1 drug use
Pizza chains face headwinds from GLP-1 drug adoption and other pressures, weighing on consumer discretionary demand.
CNBC
- Single source1 day ago
Resistance training helps GLP-1 users preserve strength despite muscle loss
GLP-1 drugs cause muscle loss; exercise and protein intake mitigate the effect.
MarketWatch
- Single source3 days ago
Daraxonrasib pill shrinks pancreatic tumors in trial patients
Pancreatic cancer drug trial shows tumour regression, advancing a treatment for one of oncology's deadliest cancers.
BBC News
- Single source3 days ago
Novartis lifts $18 billion sales target on strength in MS, cancer, lipid treatments
Novartis raises sales forecasts for blockbuster drugs to $18 billion, signaling confidence in sustained revenue growth.
CNBC
- Single source4 days ago
Weight-loss drugs reach 2.6 million British adults, present in 8.5% of households
Approximately 2.6 million adults in Great Britain use weight-loss medications, with pill formulations and growing male adoption driving adoption across roughly one in twelve homes.
The Guardian
- Single source4 days ago
Hims & Hers adds unapproved compounds despite uncertain effectiveness
Hims & Hers launches peptide treatments despite incomplete efficacy data, expanding into a high-margin wellness category.
CNBC
- Single source6 days ago
FDA rejects Summit's lung-cancer drug, stock plummets
FDA rejected a closely watched cancer drug; the biotech company's stock fell.
MarketWatch
- Single source6 days ago
Eli Lilly strikes deal beyond weight-loss drugs; Nvidia faces fresh warning
Eli Lilly strikes a deal outside its obesity franchise; CNBC flags caution on Nvidia.
CNBC
- Single source6 days ago
Novo's Wegovy reduces childhood weight in trial, opening path to younger patients
Novo Nordisk's Wegovy injection reduced BMI and obesity in children in a trial, expanding the drug's addressable market.
CNBC
- Single source6 days ago
Boots becomes first UK high street pharmacy to prescribe cannabis
The pharmacy chain will offer online medical cannabis prescriptions to patients 25 and older with conditions including chronic pain, anxiety, and insomnia.
The Guardian
- Single source8 days ago
Zimbabwe struggles to extend HIV prevention gains to youth
Zimbabwe's HIV prevention progress stalls among youth, threatening public health gains and treatment demand.
Al Jazeera
- Single source10 days ago
Pharma giants invest billions in vaccines despite political headwinds
Major pharmaceutical companies are investing billions in vaccine development amid political headwinds.
MarketWatch
- Single source11 days ago
U.S. charges Canadian healthcare executive with illegal drug smuggling
Federal authorities arrested a senior healthcare company executive on charges of illegal drug importation.
CNBC
- Single source11 days ago
Ro's revenue surges tenfold after embracing GLP-1 weight-loss drugs
Ro, a telehealth platform, revived its business through GLP-1 drug offerings and operational restructuring.
The New York Times
- Single source12 days ago
FDA requires GLP-1 makers to warn of blindness-linked eye condition
Regulators order GLP-1 drug makers to add warnings for rare eye condition linked to vision loss.
BBC News
- Single source13 days ago
FDA flags possible vision problems tied to Wegovy, Zepbound weight-loss drugs
FDA warns GLP-1 drugs including Wegovy and Zepbound carry vision loss risk.
CNBC
- Single source13 days ago
Eli Lilly's Foundayo reduces sleep apnea in late-stage testing
Eli Lilly will seek U.S. approval by year-end for its daily obesity pill to treat moderate-to-severe obstructive sleep apnea in obese adults.
CNBC
- Single source13 days ago
Novonesis pursues gut-health supplements for obesity medication users
Supplement makers see market opening as GLP-1 drugs reshape weight-loss category.
CNBC
- Single source15 days ago
Two cardiac drugs fail to beat placebo in full trial results
Two drugs failed to meet cardiologists' clinical expectations, dashing hopes for new heart disease treatments.
The New York Times
- Single source15 days ago
Study links replacement plastic chemicals to reduced fetal weight
Research finds Dinch, marketed as a safer plasticizer in food packaging, associated with smaller babies and developmental harm.
The Guardian
- Single source16 days ago
Moderna lifts 2026 revenue forecast to 15-25% growth on vaccine demand
Moderna raises 2026 guidance on stronger uptake of newer vaccine formulations.
CNBC
- Single source16 days ago
Fetal gene editing moves closer to treating rare genetic disorders
CRISPR gene-editing advances toward prenatal treatment of rare genetic diseases.
CNBC
- Single source17 days ago
Revolution Medicines' pancreatic cancer drug smashes early sales forecasts
Pancreatic cancer drug shows commercial momentum toward a blockbuster launch.
MarketWatch
- Reported by 2 outlets19 days ago
Novo lifts annual forecast on Wegovy pill sales surge
Novo Nordisk raises 2024 guidance on stronger-than-expected oral Wegovy sales.
MarketWatch · CNBC
- Single source19 days ago
Genmab shares double on cancer drug trial successes
Obscure biotech stock doubled after positive cancer trial results.
CNBC
- Single source20 days ago
Dutch authorities post €2m bounty for fugitive cocaine trafficker
Dutch police offer €2 million reward for capture of drug lord, escalating enforcement against trafficking networks.
BBC News
- Single source24 days ago
Novartis faces fresh patent cliff as pipeline drugs stumble in trials
Pharmaceutical company faces sequential patent expirations, with revenue loss from one drug offset by upcoming exclusivity cliff for another.
CNBC
- Single source24 days ago
Analyst lifts Eli Lilly price target on obesity drug momentum
CNBC raises Eli Lilly price target on sustained obesity-drug demand.
CNBC
- Single source24 days ago
Merck raises profit forecast after Keytruda sales beat expectations
Merck beats quarterly estimates and raises full-year profit guidance, driven by strong sales of a new Keytruda formulation.
CNBC
- Single source24 days ago
Eli Lilly raises full-year guidance as Zepbound, Mounjaro sales accelerate
Eli Lilly beats earnings estimates and raises full-year sales guidance, citing strong demand for obesity drugs Zepbound and Mounjaro.
CNBC
- Single source25 days ago
Traders wager against Chipotle ahead of earnings report
Traders are placing large bearish bets on a restaurant company ahead of earnings.
CNBC
- Single source26 days ago
Employers drop GLP-1 weight-loss coverage as premiums climb
Employer health plans are dropping GLP-1 drug coverage ahead of 2027, narrowing weight-loss options for workers.
CNBC
- Single source27 days ago
Cramer: Tech insiders recommend biotech stock over AI plays
Cramer reports tech insiders recommend a drug stock as a buy, citing unnamed sources.
CNBC
- Single source27 days ago
Moderna cancer vaccine enthusiasm wanes as Phase 3 data disappoints
Investor enthusiasm for Moderna's cancer vaccine candidate is waning.
MarketWatch
- Single source29 days ago
Biotech rally draws investors seeking exposure to drug innovation wave
Biotech stocks are rising on optimism about new drug innovation.
CNBC
- Single source29 days ago
Amgen drug reduces mortality 58% when paired with AstraZeneca immunotherapy
Amgen reports its drug combination reduces mortality risk by 58% in aggressive lung cancer patients.
CNBC
- Single sourceabout 1 month ago
Weight-loss drugs threaten beer sales, major brewer tells UK bars
Heineken warns UK pubs that weight-loss drug adoption will reduce beer consumption and pub visits.
The Guardian
- Single sourceabout 1 month ago
L'Oreal CEO cites weight loss drugs as drag on beauty sales
L'Oreal reports weight loss drugs are damaging beauty and skincare sales.
BBC News
- Single sourceabout 1 month ago
Guatemalan smuggler gets 30 years for deaths of 53 migrants in trailer
US court sentences Guatemalan man to 30 years for operating deadly smuggling network.
Al Jazeera
- Single sourceabout 1 month ago
Novo's experimental obesity injection produces quarter bodyweight reduction in women
Novo disclosed that CagriSema, an experimental injection, achieved greater weight reduction than its existing Wegovy treatment in late-stage testing.
CNBC
- Single sourceabout 1 month ago
Ellie Goulding apologizes for promoting Argyle mine diamonds
The Guardian
- Single sourceabout 1 month ago
Gabon seeks to shield iboga plant from commercial exploitation by US firms
Gabon moves to protect iboga plant from US pharmaceutical companies seeking to commercialize it.
The Guardian
- Single sourceabout 1 month ago
Drone and balloon smuggling operations escalate along Jordan-Israel frontier
Drug trafficking intensifies along Jordan-Israel border, creating new organized crime corridor in Middle East.
Al Jazeera
- Single sourceabout 1 month ago
Sickle cell treatments show promise despite barriers to patient access
Sickle cell gene therapies show clinical promise but face barriers to patient access and adoption.
CNBC
- Single sourceabout 1 month ago
Major health systems launch longevity medicine programs as field gains traction
New York Times examines whether longevity medicine is entering mainstream adoption and investment.
The New York Times
- Single sourceabout 1 month ago
South Australia's inaugural Michelin-starred restaurants number eleven establishments
Michelin Guide awards inaugural stars to 11 Australian restaurants, signaling prestige dining market expansion in the region.
BBC News
- Single sourceabout 1 month ago
Walmart expands worker benefits to include free diabetes and respiratory medications
Walmart expands employee benefits to cover GLP-1 drugs, inhalers, and insulin at no cost.
CNBC
- Single sourceabout 1 month ago
CEO argues reviving prehistoric animals could advance human health and conservation
Colossal Biosciences leader contends that resurrecting vanished species may yield benefits for medicine, environmental protection, and biological research.
CNBC
- Single sourceabout 1 month ago
Pokémon card prices climb as collectors navigate market complexities
CNBC
- Single sourceabout 2 months ago
Butter experiences cultural resurgence as specialty shops and collectors embrace the dairy product
Global butter demand has surged, reversing a long decline in consumption of the dairy product.
The Guardian
- Single sourceabout 2 months ago
Chief mate sentenced to 30 years after cocaine discovered aboard cargo vessel
Seafarer imprisoned for cocaine smuggling despite lack of evidence; raises questions about maritime law enforcement and due process.
The Guardian
- Single sourceabout 2 months ago
Appetite-suppressing medications weigh on restaurant sales and traffic
Weight loss drugs reduce diner appetite, pressuring restaurant traffic and spending.
The New York Times
- Single sourceabout 2 months ago
Eli Lilly and Novo Nordisk pursue amylin-based treatments for obesity
Eli Lilly and Novo Nordisk are developing amylin-based obesity drugs to follow their GLP-1 successes.
CNBC
- Single sourceabout 2 months ago
Twice-yearly HIV injection shows promise amid access concerns
HIV prevention drug advances as breakthrough, raising questions about equitable global access and distribution.
Al Jazeera
- Single sourceabout 2 months ago
Eli Lilly's dual-drug obesity treatment demonstrates stronger weight reduction in Phase 2
Eli Lilly's combination obesity treatment shows improved weight loss results in mid-stage trial.
CNBC
- Single sourceabout 2 months ago
Experimental HIV preventive injection raises concerns over global availability
New HIV vaccine candidate shows promise; access and distribution questions emerge.
Al Jazeera
- Single sourceabout 2 months ago
Grindr buys telehealth startup for $250 million to enter healthcare
Grindr acquires telehealth provider PurposeMed for $250 million, diversifying beyond dating into healthcare services.
CNBC
- Single sourceabout 2 months ago
Novo Nordisk's oral obesity drug proves effective for patients transitioning from injections
Novo Nordisk's Wegovy oral formulation maintains weight-loss efficacy in real-world patients switching from injectable GLP-1 drugs.
CNBC
- Single sourceabout 2 months ago
Two Indian nationals face charges for importing fake Ozempic from China
Federal prosecutors indicted two individuals for smuggling counterfeit versions of the diabetes drug into the United States.
CNBC
- Single sourceabout 2 months ago
Affluent individuals invest heavily in longevity treatments despite medical skepticism
Wealthy Americans spend up to $250,000 annually on longevity care; doctors weigh in on efficacy.
CNBC
- Single sourceabout 2 months ago
Novo Nordisk inks second licensing agreement after investor pushback
Novo Nordisk signs second licensing deal following recent investor relations setback.
MarketWatch
- Single sourceabout 2 months ago
Wearable ring maker Oura moves toward public market debut
Oura, a wearable health-tracking ring maker, is preparing for an initial public offering.
MarketWatch
- Single sourceabout 2 months ago
Ozempic patients advised to undergo regular eye screenings for potential sight complications
Ozempic users should get routine eye exams to assess vision loss risk, per MarketWatch health guidance.
MarketWatch
- Single sourceabout 2 months ago
Oura Health debuts on public markets through major initial offering
Oura Health goes public in a major IPO, bringing wearable health-tracking technology to public markets.
NPR
- Reported by 2 outletsabout 2 months ago
Oura delays public offering plans amid market volatility
Oura, a smart-ring maker, postpones its IPO citing market uncertainty.
NPR · CNBC
- Single sourceabout 2 months ago
Biotech investment in anti-aging races past scientific validation
Longevity science claims are outpacing evidence, raising questions about biotech and healthcare investment validity.
Al Jazeera